MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.20.02619

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes.

Garcia-Manero Guillermo, Santini Valeria, Almeida Antonio, Platzbecker Uwe, Jonasova Anna, Silverman Lewis R, Falantes Jose, Reda Gianluigi, Buccisano Francesco, Fenaux Pierre, Buckstein Rena, Diez Campelo Maria, Larsen Stephen, Valcarcel David, Vyas Paresh, Giai Valentina, Olíva Esther Natalie, Shortt Jake, Niederwieser Dietger, Mittelman Moshe, Fianchi Luana, La Torre Ignazia, Zhong Jianhua, Laille Eric, Lopes de Menezes Daniel, Skikne Barry, Beach C L, Giagounidis Aristoteles

Клиническое исследование III фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: Treatment options are limited for patients with lower-risk myelodysplastic syndromes (LR-MDS). This phase III, placebo-controlled trial evaluated CC-486 (oral azacitidine), a hypomethylating agent, in patients with International Prognostic Scoring System LR-MDS and RBC transfusion-dependent anemia and thrombocytopenia.

METHODS

Patients were randomly assigned 1:1 to CC-486 300-mg or placebo for 21 days/28-day cycle. The primary end point was RBC transfusion independence (TI).

RESULTS

Two hundred sixteen patients received CC-486 (n = 107) or placebo (n = 109). The median age was 74 years, median platelet count was 25 × 109/L, and absolute neutrophil count was 1.3 × 109/L. In the CC-486 and placebo arms, 31% and 11% of patients, respectively, achieved RBC-TI (P = .0002), with median durations of 11.1 and 5.0 months. Reductions of ≥ 4 RBC units were attained by 42.1% and 30.6% of patients, respectively, with median durations of 10.0 and 2.3 months, and more CC-486 patients had ≥ 1.5 g/dL hemoglobin increases from baseline (23.4% v 4.6%). Platelet hematologic improvement rate was higher with CC-486 (24.3% v 6.5%). Underpowered interim overall survival analysis showed no difference between CC-486 and placebo (median, 17.3 v 16.2 months; P = .96). Low-grade GI events were the most common adverse events in both arms. In the CC-486 and placebo arms, 90% and 73% of patients experienced a grade 3-4 adverse event. Overall death rate was similar between arms, but there was an imbalance in deaths during the first 56 days (CC-486, n = 16; placebo, n = 6), most related to infections; the median pretreatment absolute neutrophil count for the 16 CC-486 patients was 0.57 × 109/L.

CONCLUSION

CC-486 significantly improved RBC-TI rate and induced durable bilineage improvements in patients with LR-MDS and high-risk disease features. More early deaths occurred in the CC-486 arm, most related to infections in patients with significant pretreatment neutropenia. Further evaluation of CC-486 in MDS is needed.

Для цитирования: Garcia-Manero Guillermo, Santini Valeria, Almeida Antonio, Platzbecker Uwe, Jonasova Anna, Silverman Lewis R, Falantes Jose, Reda Gianluigi, Buccisano Francesco, Fenaux Pierre, Buckstein Rena, Diez Campelo Maria, Larsen Stephen, Valcarcel David, Vyas Paresh, Giai Valentina, Olíva Esther Natalie, Shortt Jake, Niederwieser Dietger, Mittelman Moshe, Fianchi Luana, La Torre Ignazia, Zhong Jianhua, Laille Eric, Lopes de Menezes Daniel, Skikne Barry, Beach C L, Giagounidis Aristoteles. Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021. DOI: 10.1200/jco.20.02619.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.